Mark Chao
Fondateur chez FORTY SEVEN, INC.
Postes actifs de Mark Chao
Sociétés | Poste | Début | Fin |
---|---|---|---|
FORTY SEVEN, INC. | Fondateur | 01/01/2014 | - |
Corporate Officer/Principal | 01/01/2014 | - | |
Hepatx Corp.
Hepatx Corp. Packaged SoftwareTechnology Services Hepatx Corp. engages in the provision of stem cell-based therapies for liver disease. The company was founded by Eric Schuur and Mark Chao and is headquartered in Palo Alto, CA. | Fondateur | 01/01/2015 | - |
TenSixteen Bio, Inc.
TenSixteen Bio, Inc. BiotechnologyHealth Technology TenSixteen Bio, Inc. is a genomic and clinical platform that evaluates how DNA in our cells changes over the course of our lifetimes. The company is based in San Francisco, CA. The company aims to use this evolution to inform drug discovery and treat various age-related diseases including cancer and cardiovascular disease. TenSixteen is the first company leveraging somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases. The company was founded by Mark Chao. Mark Chao has been the CEO since incorporation. | Directeur Général | 01/01/2021 | - |
Fondateur | 01/01/2021 | - | |
Foresite Labs LLC | Private Equity Investor | 01/01/2021 | - |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Consultant / Advisor | 01/12/2021 | - |
TigaTx, Inc.
TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Consultant / Advisor | 01/05/2020 | - |
Bioverge Funds Management LLC
Bioverge Funds Management LLC Investment ManagersFinance Bioverge Funds Management LLC (Bioverge Funds Management) is a venture capital subsidiary of Bioverge, Inc. founded in 2016 by Neil Jay Littman and Rick Gibb. The firm is headquartered in San Francisco, CA. | Consultant / Advisor | - | - |
Historique de carrière de Mark Chao
Anciens postes connus de Mark Chao
Sociétés | Poste | Début | Fin |
---|---|---|---|
GILEAD SCIENCES, INC. | Fondateur | - | - |
Corporate Officer/Principal | - | - |
Formation de Mark Chao
Case Western Reserve University | Undergraduate Degree |
Stanford University School of Medicine | Doctorate Degree |
Stanford University | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 12 |
Opérationnelle
Founder | 4 |
Consultant / Advisor | 3 |
Corporate Officer/Principal | 2 |
Sectorielle
Health Technology | 6 |
Consumer Services | 4 |
Technology Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
Entreprise privées | 7 |
---|---|
Forty Seven, Inc.
Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
Hepatx Corp.
Hepatx Corp. Packaged SoftwareTechnology Services Hepatx Corp. engages in the provision of stem cell-based therapies for liver disease. The company was founded by Eric Schuur and Mark Chao and is headquartered in Palo Alto, CA. | Technology Services |
TenSixteen Bio, Inc.
TenSixteen Bio, Inc. BiotechnologyHealth Technology TenSixteen Bio, Inc. is a genomic and clinical platform that evaluates how DNA in our cells changes over the course of our lifetimes. The company is based in San Francisco, CA. The company aims to use this evolution to inform drug discovery and treat various age-related diseases including cancer and cardiovascular disease. TenSixteen is the first company leveraging somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases. The company was founded by Mark Chao. Mark Chao has been the CEO since incorporation. | Health Technology |
Foresite Labs LLC | |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Health Technology |
TigaTx, Inc.
TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Health Technology |
Bioverge Funds Management LLC
Bioverge Funds Management LLC Investment ManagersFinance Bioverge Funds Management LLC (Bioverge Funds Management) is a venture capital subsidiary of Bioverge, Inc. founded in 2016 by Neil Jay Littman and Rick Gibb. The firm is headquartered in San Francisco, CA. | Finance |